Soy protein diet, but not Lactobacillus rhamnosus GG, decreases mucin-1, trefoil factor-3, and tumor necrosis factor-α in colon of dextran sodium sulfate-treated C57BL/6 mice

Journal of Nutrition

Volumn 141, Issue 7, 2011, Pages 1239-1246

  Jiang, Huanyi ^a   Przybyszewski, Joseph ^a   Mitra, Debjani ^a   Becker, Chad ^a   Brehm Stecher, Byron ^a   Tentinger, Amy ^b   MacDonald, Ruth S ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b Iowa State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN; DEXTRAN SULFATE; INTESTINAL TREFOIL FACTOR; LACTOBACILLUS RHAMNOSUS GG; MUCIN 1; PROBIOTIC AGENT; SOYBEAN PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; LACTOBACILLUS RHAMNOSUS; MOUSE; NONHUMAN; PROTEIN DIET; REAL TIME POLYMERASE CHAIN REACTION; WHEY;

ANIMALS; BASE SEQUENCE; CASEINS; CECUM; COLITIS, ULCERATIVE; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; LACTOBACILLUS RHAMNOSUS; MICE; MICE, INBRED C57BL; MILK PROTEINS; MUCIN-1; MUCINS; PROBIOTICS; RNA, MESSENGER; SOYBEAN PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

LACTOBACILLUS RHAMNOSUS; LOTUS; MUS;

EID: 79960292133     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.110.137414     Document Type: Article

References (53)

1. Vanderpool C, Yan F, Polk D. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:1585-96.
2. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-7.
3. Loftus EV Jr, Sandborn W. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:1-20.
4. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 001;91:854-62.
5. Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen T. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of populationbased cohort studies. Am J Gastroenterol. 2005;100:2724-9.
6. Jess T, Loftus EJ, Velayos F, Harmsen W, Zinsmeister A, Smyrk T, TremaineW, Melton LR, Munkholm P, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006; 12:669-76.
7. Velayos FS, Loftus EV Jr, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130:1941-9.
8. O'Connor PM, Lapointe TK, Beck PL, Buret AG. Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1411-20.
9. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut. 2001;48:132-5.
10. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2010;6:339-46.
11. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98: 694-702.
12. Yan Y, Kolachala V, Dalmasso G, Nguyen H, Laroui H, Sitaraman S, Merlin D. Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS ONE. 2009; 4:e6073.
13. Jergens AE, Dorn A, Wilson J, Dingbaum K, Henderson A, Liu Z, Hostetter J, Evans R, Wannemuehler M. Induction of differential immune reactivity to members of the flora of gnotobiotic mice following colonization with Helicobacter bilis or Brachyspira hyodysenteriae. Microbes Infect. 2006;8:1602-10.
14. Walker W. Development of the intestinal mucosal barrier. J Pediatr Gastroenterol Nutr. 2002;34 SUPPL 1:S33-9.
15. Hackam DJ, Upperman JS, Grishin A, Ford HR. Disordered enterocyte signaling and intestinal barrier dysfunction in the pathogenesis of necrotizing enterocolitis. Semin Pediatr Surg. 2005;14:49-57.
16. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep. 2010;12:319-30.
17. Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:362-81.
18. Mayer L. Mucosal immunity. Pediatrics. 2003;111:1595-600.
19. Deplancke B, Gaskins H. Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am J Clin Nutr. 2001;73: S1131-41.
20. Hoffmann W, Jagla W, Wiede A. Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol. 2001;16:319-34.
21. Khailova L, Dvorak K, Arganbright K, Halpern M, Kinouchi T, Yajima M, Dvorak B. Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2009;297:G940-9.
22. Moon G, Myung S, Jeong J, Yang S, Cho Y, Lee S, Chang H, Byeon J, Lee Y, et al. Prophylactic effect of Lactobacillus GG in animal colitis and its effect on cytokine secretion and mucin gene expressions. Korean J Gastroenterol. 2004;43:234-45.
23. Shah NP. Effects of milk-derived bioactives: an overview. Br J Nutr. 2000;84 SUPPL 1:S3-10.
24. Farnworth ER, Mainville I, Desjardins MP, Gardner N, Fliss I, Champagne C. Growth of probiotic bacteria and bifidobacteria in a soy yogurt formulation. Int J Food Microbiol. 2007;116:174-81.
25. Tsinberg M, Deriabin D, Denisova I, Nikiian A. [Growth and morphological characteristics of industrial strains of Bifidobacterium and Lactobacillus cultivated in hydrolysate-milk and hydrolysate-soybean media]. Antibiot Khimioter. 2003;48:9-13.
26. Cai X, Yuan J, Xiao Z. Alleviating radiation damage and protecting the bowel barrier functions in the SD rats using the soy protein. Chinese J Clin Nutr. 001;9:16-9.
27. Goldin BR, Gorbach SL, Saxelin M, Barakat S, Gualtieri L, Salminen S. Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci. 1992;37:121-8.
28. Saxelin M. Lactobacillus GG: a human probiotic strain with thorough clinical documentation. Food Rev Int. 1997;13:293-313.
29. Salminen SJ, Seppo J, Donohue DC. Safety assessment of Lactobacillus strain GG (ATCC 53103). Nutr Today. 1996;31:16.
30. Reeves PG. Components of the AIN-93 diets as improvements in the AIN-76A diet. J Nutr. 1997;127:S838-41.
31. Suzuki R, Kohno H, Sugie S, Nakagama H, Tanaka T. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfateinduced colon carcinogenesis in mice. Carcinogenesis. 2006;27:162-9.
32. Gallup JM, Ackermann MR. Addressing fluorogenic real-time qPCR inhibition using the novel custom Excel file system 'FocusField2-6GallupqPCRSet-upTool-001' to attain consistently high fidelity qPCR reactions. Biol Proced Online. 2006;8:87-152.
33. Larouche D, Lavoie A, Paquet C, Simard-Bisson C, Germain L. Identification of epithelial stem cells in vivo and in vitro using keratin 19 and BrdU. Methods Mol Biol. 2010;585:383-400.
34. Ahlroos T, Tynkkynen S. Quantitative strain-specific detection of Lactobacillus rhamnosus GG in human faecal samples by real-time PCR. J Appl Microbiol. 2009;106:506-14.
35. Sprong RC, Schonewille AJ, van der Meer R. Dietary cheese whey protein protects rats against mild dextran sulfate sodium-induced colitis: role of mucin and microbiota. J Dairy Sci. 2010;93:1364-71.
36. Pham TT, Shah NP. Fermentation of reconstituted skim milk supplemented with soy protein isolate by probiotic organisms. J Food Sci. 2008;73: M62-6.
37. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995;109:1344-67.
38. Reed KL, Fruin AB, Gower AC, Gonzales KD, Stucchi AF, Andry CD, O'Brien M, Becker JM. NF-kappaB activation precedes increases in mRNA encoding neurokinin-1 receptor, proinflammatory cytokines, and adhesion molecules in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci. 2005;50:2366-78.
39. Hoebler C, Gaudier E, De Coppet P, Rival M, Cherbut C. MUC genes are differently expressed during onset and maintenance of inflammation in dextran sodium sulfate-treated mice. Dig Dis Sci. 2006;51:381-9.
40. Plaut AG. Trefoil peptides in the defense of the gastrointestinal tract. N Engl J Med. 1997;336:506-7.
41. Matsuo K, Ota H, Akamatsu T, Sugiyama A, Katsuyama T. Histochemistry of the surface mucous gel layer of the human colon. Gut. 1997;40:782-9.
42. Furr A, Ranganathan S, Finn O. Aberrant expression of MUC1 mucin in pediatric inflammatory bowel disease. Pediatr Dev Pathol. 2010;13:24-31.
43. Van der Sluis M, De Koning B, De Bruijn A, Velcich A, Meijerink J, Van Goudoever J, Büller H, Dekker J, Van Seuningen I, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131:117-29.
44. Faure M, Moënnoz D, Montigon F, Mettraux C, Mercier S, Schiffrin E, Obled C, Breuillé D, Boza J. Mucin production and composition is altered in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci. 2003;48:1366-73.
45. Renes IB, Verburg M, Van Nispen DJ, Taminiau JA, Büller HA, Dekker J, Einerhand AW. Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression. Int J Colorectal Dis. 2002;17: 317-26.
46. Kjellev S, Thim L, Pyke C, Poulsen S. Cellular localization, binding sites, and pharmacologic effects of TFF3 in experimental colitis in mice. Dig Dis Sci. 2007;52:1050-9.
47. Podolsky DK. Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides. J Gastroenterol. 2000;35 Suppl 12:69-74.
48. Mashimo H, Wu D, Podolsky D, Fishman M. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science. 1996; 274:262-5.
49. Guo JY, Li X, Browning JD, Rottinghaus GE, Lubahn DB, Constantinou A, Bennink M, MacDonald RS. Dietary soy isoflavones and estrone protect ovariectomized ERalphaKO and wild-type mice from carcinogen-induced colon cancer. J Nutr. 2004;134:179-82.
50. Hernández-Ledesma B, Hsieh C, de Lumen B. Antioxidant and antiinflammatory properties of cancer preventive peptide lunasin in RAW 264.7 macrophages. Biochem Biophys Res Commun. 2009;390:803-8.
51. Gonzalez de Mejia E, Vásconez M, de Lumen B, Nelson R. Lunasin concentration in different soybean genotypes, commercial soy protein, and isoflavone products. J Agric Food Chem. 2004;52:5882-7.
52. Gupta P, Andrew H, Kirschner B, Guandalini S. Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, openlabel study. J Pediatr Gastroenterol Nutr. 2000;31:453-7.
53. Amit-Romach E, Uni Z, Reifen R. Therapeutic potential of two probiotics in inflammatory bowel disease as observed in the trinitrobenzene sulfonic acid model of colitis. Dis Colon Rectum. 2008;51:1828-36.